Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
Tóm tắt
Prostate cancer cells, like normal prostate epithelial cells, produce high levels of the differentiation marker and serine protease prostate‐specific antigen (PSA). PSA is used extensively as a biomarker to screen for prostate cancer, to detect recurrence following local therapies, and to follow response to systemic therapies for metastatic disease. While much is known about PSA's role as a biomarker, only a relatively few studies address the role played by PSA in the pathobiology of prostate cancer. Autopsy studies have documented that not only do prostate cancer cells maintain production of high amounts of PSA but they also maintain the enzymatic machinery required to process PSA to an enzymatically active form. A variety studies performed over the last 10 years have hinted at a role for PSA in growth, progression, and metastases of prostate cancer. A fuller understanding of PSA's functional role in prostate cancer biology, however, has been hampered by the lack of appropriate models and tools. Therefore, the purpose of this review is not to address issues related to PSA as a biomarker. Instead, by reviewing what is known about the genetics, biochemistry, and biology of PSA in normal and malignant prostate tissue, insights may be gained into the role PSA may be playing in the pathobiology of prostate cancer that can connect measurement of this biomarker to an understanding of the underlying etiology and progression of the disease. Prostate 67:312–329, 2007. © 2006 Wiley‐Liss, Inc.
Từ khóa
Tài liệu tham khảo
Berges RS, 1995, Implication of the cell kinetic changes during the progression of human prostatic cancer, Clin Cancer Res, 1, 473
Pinski J, 2001, Therapeutic implications of enhanced G0/G1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts, Cancer Res, 61, 6372
Bostwick DG, 2000, Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999, Arch Pathol Lab Med, 124, 995
Lilja H, 1989, Semenogelin, the predominant protein in human semen, J Biol Chem, 264, 1894, 10.1016/S0021-9258(18)94272-9
Denmeade SR, 1997, Specific and efficient peptide substrates for assaying the proteolytic activity of prostate specific antigen, Cancer Res, 57, 4924
Lilja H, 2000, Comprehensive Textbook of Genitourinary Oncology, 638
Evans BA, 1987, Mouse glandular kallikrein genes. Structure and partial sequence analysis of the kallikrein gene locus, J Biol Chem, 262, 8027, 10.1016/S0021-9258(18)47521-7
Karr JF, 1995, The presence of prostate‐specific antigen‐related genes in primates and the expression of recombinant human specific antigen in a transfected murine cell line, Cancer Res, 55, 2455
Denmeade SR, 1998, Enzymatic‐activation of a doxorubicin‐peptide prodrug by prostate‐specific antigen, Cancer Res, 58, 2537
Kumar A, 1997, Expression of pro form of prostate‐specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2, Cancer Res, 57, 3111
Herrala A, 1998, Androgen‐sensitive human prostate cancer cells, LNCaP, produce both N‐terminally mature and truncated prostate‐specific antigen isoforms, Eur J Biochem, 98, 32
Lilja H, 1991, Prostate‐specific antigen in serum occurs predominantly in complex with α1‐antichymotrypsin, Clin Chem, 37, 1618, 10.1093/clinchem/37.9.1618
Stenman UH, 1991, A complex between prostate specific antigen and α1‐antichymotrypsin is the major form of prostate‐specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer, Cancer Res, 51, 222
Pettersson K, 1995, Free and complexed prostate‐specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA‐alpha 1‐antichymotrypsin complex, Clin Chem, 41, 1480, 10.1093/clinchem/41.10.1480
Koo PH, 1994, Monoamine‐activated alpha 2‐macroglobulin binds trk receptor and inhibits nerve growth factor‐stimulated trk phosphorylation and signal transduction, J Biol Chem, 269, 5369, 10.1016/S0021-9258(17)37696-2
Bhattacharjee G, 2000, The conformation‐dependent interaction of alpha 2‐macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2‐macroglobulin/growth factor binding, J Biol Chem, 275, 26806, 10.1016/S0021-9258(19)61447-X
Sakr WA, 1994, High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: An autopsy study of 249 cases, In Vivo, 8, 439
Miller GJ, 2000, Advanced Therapy of Prostate disease, 18
de Lamirande E, 2001, Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process, J Androl, 22, 672, 10.1002/j.1939-4640.2001.tb02228.x
Jonsson M, 2005, Semenogelins I and II bind zinc and regulate the activity of prostate‐specific antigen, Biochem J, 387, 447, 10.1042/BJ20041424
Lissbrant IF, 2000, Tumor associated macrophages in human prostate cancer: Relation to clinicopathological variables and survival, Int J Oncol, 17, 445
Webber MM, 1995, Prostate‐specific antigen, a serine protease, facilitates human prostate cancer cell invasion, Clin Cancer Res, 1, 1089
Gygi CM, 2002, Prostate‐specific antigen (PSA)‐mediated proliferation, androgenic regulation and inhibitory effects of LY312340 in HOS‐TE85 (TE85) human osteosarcoma cells, Anticancer Res, 22, 2725
Chirgwin JM, 2004, Tumor‐bone cellular interactions in skeletal metastases, J Musculoskelet Neuronal Interact, 4, 308
Shim EH, 2003, Expression of the F‐box protein SKP2 induces hyperplasia, dysplasia, and low‐grade carcinoma in the mouse prostate, Cancer Res, 63, 1583
Yang G, 2002, Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin‐dependent kinase inhibitor p27 and PTEN and with reduced recurrence‐free survival, Clin Cancer Res, 8, 3419